A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Arm, Parallel-Group Study in Pediatric Subjects Aged 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 and BIIB017 for the Treatment of Relapsing-Remitting Multiple Sclerosis

drug protocol number
800MS301
drug sponsor
Biogen
drug study
Dimethyl fumarate and PEGylated Interferon Beta-1a
drug trial site
KKUH
drug status
Completed
drug phase